
Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery.

Patients with advanced ovarian cancer who achieved complete cytoreduction had the best outcomes, regardless of the number of chemotherapy cycles before surgery.

Being told to write was the best advice I could have ever received.

A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.

An expert gives an overview of up-and-coming treatments for patients with kidney cancer.

Long-term follow-up data showed that Lenvima plus Keytruda continued to show benefit in patients with metastatic kidney cancer.

Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.

I couldn't believe that I would benefit from some of the side effects of my cancer treatment.

Radiation is an emerging treatment modality in kidney cancer. Research shows that it is effective and helps patients maintain a good quality of life.

Keytruda after nephrectomy improved disease-free survival rates in patients with clear cell renal cell carcinoma regardless of disease risk or stage.

Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.

From Stand Up to Cancer honoring survivors at a Minor League baseball game, to Maria Menounos showing her cancer scars on Instagram, here’s what’s happening in the oncology space this week.

A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.

Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.

Palliative care can benefit patients with advanced cancer by integrating advanced care planning, pain and symptom management and counseling, among other aspects.

After being diagnosed with cancer, I experienced the fear of missing out, but eventually replaced it with the joy of missing out.

When it comes to a physical exam, you don’t know how much of an impact it could make.
Darcie Green, executive director of service and advocacy organization Latinas Contra Cancer, tells the CURE® “Cancer Horizon” podcast about how its work has broadened over the last 20 years.

Staging a laparoscopy can help patients with pancreatic cancer identify the stage of cancer, where it spread and what the best treatment may be, a recent study shows.

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The Food and Drug Administration accepted a supplemental New Drug Application for Brukinsa plus Gazyva to treat patients with relapsed or refractory follicular lymphoma.

Looking back on the nine years since being diagnosed with breast cancer, here are my perceptions and reflections of the disease.

I think it was Theodore Geisel (aka Dr Seuss) who said “Don’t cry because it’s over, smile because it happened.”

Writing about my breast cancer experience became cathartic to me, and eventually my journal entries were compiled into a book, “Feisty Righty.”

Treatment time for patients with early-detected breast cancer may be reduced by one week with the use of simulated integrated boost (SIB) radiotherapy.

Adolescents and young adults undergoing VEGF treatment for nonmetastatic, high-risk renal cell carcinoma may still experience heart-related conditions like left ventricular systolic dysfunction and high blood pressure.

Immunotherapy with Opdivo plus cisplatin-based chemotherapy improved overall survival and progression-free survival in patients with unresectable or metastatic urothelial carcinoma.

I remember my first trip to the “chemo room”.

Disease symptoms, as well as other health conditions, can have a major impact on the treatment plan for patients with myeloproliferative neoplasms.

Fruquintinib improved overall survival compared with placebo in patients with refractory metastatic colorectal cancer.